ZURICH, SWITZERLAND / ACCESSWIRE / May 2, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development
NLS Pharmaceutics (NLSP) Cleared by FDA to Proceed with Phase 3 Clinical Program for Quilience streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
IND opened and Fast Track Designation granted by FDA for Erythromelalgia First patients enrolled in ACT study in Chemotherapy-Induced Peripheral Neuropathy European biotech AlgoTx, a clinical
Patients treated with Mazindol ER in the randomized Phase 2 trial showed continued improvement after rolling over into the open label extension (OLE) studyPatients treated with placebo in the randomized
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2 kansascity.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kansascity.com Daily Mail and Mail on Sunday newspapers.